The Cancer & Stem Cell Research Segment is Expected to Register the Highest CAGR in 3D Cell Culture Market - Markets and Markets

By -

The increasing incidence of cancer and significant funding initiatives for cancer research from government as well as private organizations are supporting the growth of this application.

(EMAILWIRE.COM, July 04, 2019 ) The 3D cell culture market is expected to reach $1,720.3 Million by 2022 from $570.4 Million in 2016 growing at a CAGR of 20.3%

The Research report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the 3D Cell Culture Market, along with revenue estimates & forecasts and market share analysis.

Moreover, the study showcases back-to-back parameters like application, improvement, product growth, and diverse structures & key processes. The report highlights the in-depth analysis of various critical parameters such as profit & loss statistics, product value, production capability, production process, and many more.

Factors such as rising focus on developing alternative methods for animal testing, funding initiatives from government and private investors, technological advancements and product launches, and growing awareness are driving the growth of the market.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191072847

3D Cell Culture Market Segmentation:

1. By Product
2. By Application
3. By End Users
4. By Region

The Major Players Opearting in the 3D Cell Culture Market are:

Prominent players in this market include Thermo Fisher (US), Corning (US), Lonza (Switzerland), Merck (Germany), ReproCELL (Japan), and InSphero (Switzerland). The other players operating in this market include Global Cell Solutions (US.), Synthecon (US), 3D Biotek (US), Kuraray (Japan), Hamilton Company (US), Mimetas (Netherlands), Emulate (US), Nano3D Biosciences (US), and QGel (Switzerland).

Thermo Fisher was the leading player in the 3D cell culture market in 2016. The company’s leading position is primarily attributed to its strong brand image and product portfolio. Thermo Fisher constantly focuses on strengthening its product portfolio. For instance, in 2014, the company introduced Nunclon Sphera, a polymer-coated cell culture surface with low-binding characteristics, which supports the growth of 3D cancer spheroids and embryoid bodies. The company has a strong presence in over 100 countries across the Americas, Asia Pacific, Europe, and the Middle East & Africa.

Geographical Analysis Of 3D Cell Culture Market:

The market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as increase in incidence of cancer, presence of well-established pharmaceutical and biotechnology industry, and availability of technologically advanced products.

Read more: https://www.marketsandmarkets.com/PressReleases/3d-cell-culture.asp

Read other news from MarketsandMarkets™

Timing Devices Market Size, Share, Revenue Trends & Forecast to 2030

MarketsandMarkets™ - Sep 18, 2023
Timing Devices Market by Type (Oscillators, Atomic Clocks, Clock Generators, Clock Buffers, Jitter Attenuators), Material (Crystal, Silicon, Ceramic), Vertical (Consumer Electronics, Automotive) and Region - Global Forecast to 2030 ...Read more

Artificial Intelligence Market Segmented by Product, Top Manufacturers, Geography Trends & Growth Opportunity to 2030

MarketsandMarkets™ - Sep 18, 2023
Artificial Intelligence technology such as machine learning, natural language processing, computer vision, and others are revolutionizing various sectors, including healthcare, finance, manufacturing, and retail. ...Read more

Digital PCR (dPCR) and Real-time PCR (qPCR) Market worth $12.4 billion by 2028, at a CAGR of 7.8%.

MarketsandMarkets™ - Sep 18, 2023
"Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospital, Diagnostic Labs, Pharma, Biotech, CROs) - Global Forecast to 2028". ...Read more